Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 24:2013:196541.
doi: 10.1155/2013/196541. eCollection 2013.

Profiling the prognosis of gastric cancer patients: is it worth correlating the survival with the clinical/pathological and molecular features of gastric cancers?

Laura Lorenzon  1 , Paolo Mercantini  1 , Mario Ferri  1 , Marco La Torre  1 , Alessandra Sparagna  1 , Genoveffa Balducci  1 , Giulia Tarantino  1 , Adriana Romiti  2 , Emanuela Pilozzi  2 , Vincenzo Ziparo  1
Affiliations

Profiling the prognosis of gastric cancer patients: is it worth correlating the survival with the clinical/pathological and molecular features of gastric cancers?

Laura Lorenzon et al. ScientificWorldJournal. .

Abstract

Background: The prognosis of gastric cancer patients still remains poor. The aim of this study was investigating the prognostic value of several clinical/pathological/molecular features in a consecutive series of gastric cancers.

Methods: 150 R0 gastrectomies plus 77 gastric cancer patients evaluated for the HER2 overexpression were selected. Survival was calculated and patients stratified according to the stage, the T-stage, the LNRs, the LNH, and the HER2 scoring system. ROC curves were calculated in order to compare the performance of the LRN and LNH systems.

Results: Prognosis correlated with the stage and with the T-stage. We documented a statistical correlation between the LNRs and the survival. Conversely, a LNH > 15 did not correlate with the outcomes. The ROC curves documented a significant performance of the LRN system, whereas a statistical correlation was documented for the LNH exclusively with the endpoint of disease-free survival. We documented a trend of worse prognosis for patients with an HER2 overexpression, even though it was not of statistical value.

Conclusion: The LNR and the evaluation of the HER2 overexpression might be useful since they correlate with survival, might identify patients with a higher risk of recurrence, and might select patients for a tailored medical treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical and pathological features of patients undergoing R0 gastrectomy for gastric adenocarcinoma 2003 to 2011 at our Department including the M/F ratio, the localization of the tumors and the surgical treatments, the stage of the diseases, the grading of the tumors, the LNR and the LNH subgroups, the cellular types and Lauren classification, along with the rate of adjuvant treatment performed in our series.
Figure 2
Figure 2
Gastric cancer and survivals. (a) Overall survival, disease free survival, and disease specific survival of R0 gastric resection for adenocarcinoma of the stomach; (b) overall survival, disease free survival, and disease specific survival analysis according to the Stage of the disease; (c) overall survival, disease free survival and disease specific survival according to the depth of tumors infiltration (T-Stage).
Figure 3
Figure 3
Gastric cancer and LNR/LNH related survivals. (a) Overall survival, disease free survival, and disease specific survival of R0 gastric resection for adenocarcinoma of the stomach according with the LNH subgroups; (b) overall survival, disease free survival, and disease specific survival analysis according to the LNR subgroups.
Figure 4
Figure 4
Gastric cancer and ROC curve analysis. (a) Overall survival, disease free survival, and disease specific survival ROC curves according to the LNH parameter; (b) overall survival, disease free survival, and disease specific survival ROC curves according to the LNR parameter.
Figure 5
Figure 5
Gastric cancer and HER2 overexpression related survivals. (a) Overall survival, disease free survival and disease specific survival of gastric cancers according to the IHC scoring; (b) overall survival, disease free survival and disease specific survival analysis: negative tumors (HER2 0 and HER2 1+) versus equivocal/positive tumors (HER2 2+ and HER2 3+); (c) overall survival, disease free survival and disease specific survival: positive tumors (HER2 3+) versus other negative/equivocal tumors (HER2 0, HER2 1+, HER 2 2+).
See this image and copyright information in PMC

References

    1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of Clinical Oncology. 2006;24(14):2137–2150. - PubMed
    1. AIRTUM. I tumori in Italia: Rapporto. 2006, http://www.registri-tumori.it/incidenza1998-2002/gruppi.html.
    1. American Joint Committee on Cancer. Manual for Staging of Cancer. 4th edition. New York, NY, USA: Lippincott-Raven; 1992.
    1. American Joint Committee on Cancer. Manual for Staging of Cancer. 5th edition. New York, NY, USA: Lippincott-Raven; 1997.
    1. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Annals of Surgery. 2000;232(3):362–371. - PMC - PubMed

Publication types

MeSH terms